1. Platelets containing adenine nucleotides labelled with 3H and 14C in vitro were aggregated biphasically with ADP and adrenaline. Amounts of ATP and ADP as well as the radioactivity of ATP, ADP, AMP, IMP, hypoxanthine and adenine were determined in platelets and plasma at different stages of aggregation. 2. ATP and ADP were released during the second aggregation phase and had a low specific radioactivity compared with the ATP and ADP retained by the cells. The specific radioactivity of intracellular nucleotides increased during release. The parameters observed with ADP and adrenaline as release inducers were the same as for collagen and thrombin. 3. Release induced by all four inducers was accompanied by conversion ofcellular [3H]ATP into extracellular [3H]-hypoxanthine. By variation of temperature, inducer concentration, time after blood withdrawal and use of acetylsalicylic acid, the aggregation pattern caused by adrenaline and ADP could be made mono-or bi-phasic. Release or second-phase aggregation was intimately connected with the ATP-hypoxanthine conversion, whereas first phase aggregation was not. 4. The [3H]ATP-hypoxanthine conversion started immediately after ADP addition. With adrenaline it usually started with the appearance of the second aggregation phase. The conversion was present during first phase of ADP-induced aggregation only if a second phase were to follow. 5. When secondary aggregation took place while radioactive adenine was being taken up by the platelets, increased formation of labelled hypoxanthine still occurred, but there was either no change or an increase in the concentration of labelled ATP. 6. Biphasically aggregated platelets converted [3H]adenine more rapidly into [3H]-ATP and -hypoxanthine than non-aggregated platelets. Addition of [3H]adenine at different stages of biphasic aggregation showed that more [3H]hypoxanthine was formed during than after the release step. 7. We conclude that ADP and adrenaline, like thrombin and collagen, cause extrusion of non-metabolic granula-located platelet adenine nucleotides. During release metabolic ATP breaks down to hypoxanthine, and this process might reflect an ATP-requiring part of the release reaction.
4H. HOLMSEN, H. J. flAY AND C. A. SETKOWSKY Scheme 1. Representation of the adenine nucleotide metabolism in resting and release-stimulated platelets Radioactive precursors (*Pi, *adenine and *adenosine) can enter the cell and label the metabolic pool of platelet nucleotides; all members of this pool are designated by *. The fairly good balance between ATP resynthesis via glycolysis+oxidative phosphorylation, and the energy-utilizing processes in the resting cell, keeps the concentrations of metabolic ATP, ADP and AMP in the platelet-rich plasma almost constant for hours. However, a small amount of the metabolic nucleotides in the resting cells is catabolized to hypoxanthine, which diffuses into the medium (upper right). In human platelets about two-thirds of the adenine nucleotides form the non-metabolic (storage) pool (0), are stored in granules and do not participate in metabolism. Upon release-stimulation by thrombin and collagen this pool is extruded through channels to the surrounding medium (broken, double-lined arrow). Concomitant with this extrusion a certain amount of metabolic ATP is rapidly degraded to hypoxanthine, which diffuses out of the cell.
nucleotides. This pool (two-thirds of adenine nucleotides in human platelets) is not labelled in vitro by radioactive adenosine, adenine or orthophosphate, and is stored in subcellular granules (Holmsen et al., 1969a) . The metabolic pool present in cytosol, membranes and mitochondria, is labelled in vitro, and is retained during the release reaction. During release induced by thrombin and collagen, a certain fraction of metabolic ATP is converted into IMP and hypoxanthine (Ireland, 1967; Holmsen et al., 1969a) . Scheme 1 summarizes platelet adenine nucleotide compartmentalization and behaviour during the release reaction.
The present study describes the metabolic nature of the adenine nucleotides that are released and retained, as well as their intracellular conversions during ADPand adrenaline-platelet interaction. Comparison has been made with thrombin-and collagen-platelet interaction. The behaviour of radioactive adenine metabolites during biphasic aggregation at different stages of [3H] adenine uptake has also been studied.
Experimental Materials
Chemicals. ADP (disodium salt from equine muscle; Sigma Chemical Co., St. Louis, Mo., U.S.A.), was stored in small portions (400,ug/ml in 0.15M-NaCl) at -60°C and diluted with 0.15M-NaCl to the desired concentrations imnediately before use. The 1972 exact concentration of ADP stock solutions was determined as described by Holmsen & Storm (1969) . L-Adrenaline bitartrate from Winthrop Laboratories (New York, N.Y., U.S.A.) was stored at a concentration of Smg/ml in 0.15M-NaCl at -60°C and thawed immediately before use. Solutions were kept on ice during the experiment and discarded afterwards.
Acetylsalicylic acid (United States Pharmacopeia grade; Merck, Rahway, N.J., U.S.A.), was dissolved in 0.12M-NaHCO3 and stored at 4°C. Soluble collagen was prepared and stored as described by Holmsen & Weiss (1972) . It was used in an undiluted form.
Radiochemicals. [G-3H] Adenine (NET-063, New England Nuclear Corp., Boston, Mass., U.S.A.), 6000mCi/mmol, was supplied as 0.113mg of adenine in 5.0ml of water. It was diluted with 0.15 M-NaCl to 16.7 or 40tM, and these stock solutions were stored in portions at -60°C. They were refrozen after use.
[8-'4C]Adenosine (NEC-524, New England Nuclear Corp.) 33.5mCi/mmol in aq. 50% (v/v) ethanol, was dried with a N2 jet (room temperature) and redissolved to a concentration of 308.tM in 0.15M-NaCl and kept at -60°C. It was refrozen after use.
[U-14C]Adenine (Schwarz Bio-Research, Orange- 40, adenine/ml of platelet-rich plasma. The
[3H]adenine in incubation mixture 1 was fully incorporated by the platelets after 45min at 37'C or 60-75min at room temperature. Incubation mixture 2 was used to study adenine uptake during aggregation.
[8-14C]Adenosine-labelled platelet-rich plasma. Platelet-rich plasma (20vol.) was incubated for 60min at 37°C with 308/p&M-[8-14C]adenosine (1 vol.) .
Methods
Platelet aggregation. This was measured by reading the changes of light-transmission when light was passed through platelet-rich plasma. The deflection of each platelet-rich plasma was adjusted to 10% of full scale on the recorder with the autologous platelet-poor plasma to give a slightly off-scale (105-120% of the full scale) reading. The experiments were done in an EEL titrator (Evans Electroselenium Ltd., Halstead, Essex, U.K.) provided with a 605 filter and a constant temperature-controlled copper block, and connected via a galvanometer (EEL, Unigalvo, type 200; Evans Electroselenium Ltd.) to one of the following recorders: Heath Servo (model EU 20B), Sargent (model SRL) or Perkin-Elmer (Coleman 165; from Norwalk, Conn., U.S.A.). With the last-named the circuit was fed with a variable backing-off e.m.f. (0-12mV) derived from a mercury cell to obtain full-scale zero suppression. The heating block had several copper adaptors for cuvettes of variable size, to facilitate heat conduction from the heating block to the cuvettes (6-8 mm inner diam., round-bottomed). The cuvette contents were stirred by a plastic-covered magnetic stirrer (5mm long x 4.5mm diam.) at the titrator's maximum speed.
Radioactive platelet-rich plasma (1.8-2.Oml) was pipetted into the cuvette, and after temperature equilibration for 1-2min, 0.2ml ofADP or adrenaline was added. At noted times, 200-or 100-p,l samples were rapidly transferred into plastic tubes containing 200 or 100,ul respectively ofEDTA-ethanol . The plasma-EDTA-ethanol mixtures were kept in ice until removal of precipitates by centrifugation (4°C, 10min, 17500gmax.. The supernatants, referred to as EDTA-ethanol extracts, were kept at -20°C or -60°C until analysed, usually within 2-3 days.
The smaller cuvettes could be centrifuged, which made it possible to separate cells and plasma before Haslam (1964) (with the EDTA concentration increased to 4.8mM) in a volume equal to that of the mixture they were isolated from. Finally, one volume of aq. 96% ethanol was added. Both types of ethanol mixtures were kept on ice with occasional stirring for 10min, and the sediments were removed by centrifugation as described above. The supernatants, referred to as 'EDTA-ethanol extracts', were saved and stored as described above.
In some experiments an EEL platelet-aggregation meter (model 169, Evans Electroselenium Ltd.) was used (37°C). The cuvette contents were poured into ice-cold 5ml plastic tubes containing 0.1 ml of 0.1 M-EDTA/ml of cuvette contents, and centrifuged, then extracted and stored as described above.
Determination of ATP and ADP. The concentrations of the adenine nucleotides were determined in the EDTA-ethanol extracts by a luciferin-luciferase method (HIolmsen et al., 1972) .
Determination of adenine and adenosine metabolite radioactivity. This was done as described previously (Holmsen & Weiss, 1970 Table 2 . Distribution ofamounts and radioactivity ofATP and A DP in platelets andplasma from the aggregation experiment with adrenaline illustrated in Fig. 2 For details see Fig. 2 and Fig Tables 1 and 2 show the amounts and radioactivity of platelet ATP and ADP in platelets and plasma at different stages of aggregation in the corresponding experiments. In both cases, 30-S50 % of platelet ATP and ADP were released during the second phase of aggregation, and the specific radioactivity of these nucleotides was low compared with that of the nuclootides remaining in the platelets. After release the specific radioactivity of cellular ATP and particularly ADP was higher than in the control cells or during the first phase of aggregation. Use of [8-4C] adenosine-or [3H]-adenine-labelled platelet-rich plasma gave identical results.
Changes in distribution of adenine metabolites after biphasic platelet aggregation caused by ADP and adrenaline in platelet-rich plasma after adenine uptake Adenine added to platelet-rich plasma is exclusively metabolized by the platelets (Holmsen & Rozenberg, 1968) to cellular ATP, ADP, AMP, IMP and hypoxanthine, the last-named appearing in plasma. This distribution can be sen from Table 3 (NaCl-treated platelet-rich plasma). After biphasic aggregation by adrenaline the intracellular concentration of radioactive ATP had decreased by more than 20%. This was mainly accounted for by an increase in the radioactivity of extracellular hypoxanthine, in particular, and cellular IMP and hypoxanthine (Table 3) Table 2 . (Table 3 ) and increases (Tables 1 and 2 ) were noted. Small but varied amounts of ATP and ADP radioactivity were present in extracts of plasma from biphasically aggregated platelet-rich plasma (see Tables 3 and 4 ). This has been considered to indicate unspecified lysis of few platelets during release . However, the main changes in the metabolic nucleotides during ADP-and adrenaline-induced release were the cellular breakdown of ATP and the extracellular accumulation of hypoxanthine (Table 3) . With samples ofa given [3H]adenine-labelled platelet-rich plasma, the same degree of aggregation was achieved by all four inducers within about 5min (Fig. 3) . The amounts of ATP and ADP released and the amounts and specific radioactivity of the remaining cellular nucleotides were essentially the same for the four inducers (Table 4) . No difference was found between the ability of the inducers to cause conversion of cellular [3H]ATP into extracellular radioactive hypoxanthine (Table 4) .
The experiment recorded in Table 4 and Fig. 3 exemplifies a situation with a high degree of platelet lysis during release (presence of radioactive nucleoside phosphates extracellularly after release). Usually, lysis corresponded to less than 2 % of the total platelet nucleotide radioactivity appearing extracellularly. Therefore the difference in specific radioactivity between released and retained ATP and ADP was less in the experiment recorded in Table 4 than usual. Nevertheless, the experiment shows that when lysis occurs during the release reaction, it occurs with any of the four release inducers investigated.
Association of the ATP-hypoxanthine conversioni with the secondphase (release step) ofaggregation Human platelets aggregate biphasically above 30°C and within certain concentrations of ADP and adrenaline. Below the threshold concentrations only the first phase of aggregation occurs, without nucleotide release (Hardisty et al., 1970) . Above the upper concentration release occurs, but owing to the maximal rate of primary aggregation, light-transmission recording cannot show the onset of the second phase. Conditions can thus be selected with either pure firstphase aggregation or well-recorded biphasic aggregation by (a) variation of aggregation temperature, or (b) variation of ADP and adrenaline concentrations.
The ability of platelets to respond with biphasic aggregation to adrenaline and ADP (in particular) varied greatly within the first 3h after blood collection. Thus numerous experiments had to be abandoned because the platelets failed to aggregate biphasically after incubation with radioactive compounds, although they had responded properly before incubation. This failure ('second phase fatigue') was not due to metabolism of the compounds, and provided a third (c) condition of studying the association of ATP-hypoxanthine conversion with either phase of aggregation. A fourth way to alter biphasic aggregation is (d) use of acetylsalicylate, which blocks the second phase of aggregation induced by adrenaline (O'Brien, 1968a) and ADP (Zucker & Peterson, 1968) , without affecting the first phase. added. Samples (lOO,ul) of the reaction mixture were transferred into lOO,ul of EDTA-ethanol at the times indicated. After the 8-mmn sample had been transferred, 0.2ml of 0.077M-EDTA (pH7.4) was added to the remainder in the cuvettes, and the cuvette was centrifuged. EDTA-ethanol extracts were prepared from cells and plasma as described in the Experimental section. An increase in IMP+hypoxanthine radioactivity was always paralleled by a corresponding decrease in the ATP+ADP radioactivity. For practical reasons the time-sequence of aggregation experiments was from the lowest to the highest temperature, and the NaCl control was always done after aggregation, at the highest temperature. (Fig. 4, Table 6 ). At intermediate concentrations, giving secondary aggregation with a submaximal rate (Fig. 4c) , the amount of hypoxanthine+IMP formed varied between 2% and the maximum value.
(c) Occurrence of 'second phase fatigue'. Plateletrich plasma, which no longer showed biphasic aggregation with ADP after incubation with isotopes, had insignificant formation of hypoxanthine+IMP (2% of total radioactivity). The Table 7 . Effect of aspirin on nucleotide release and ATP-hypoxanthine conversion A sample (lOml) of platelet-rich plasma (4.55 x 108 platelets/ml) was incubated at room temperature for 60min with 100lul of 40,LM-[3H]adenine. Portions (1.5ml) were incubated with 0.15ml of 0.15M-NaCl or 8mM-aspirin for 10min at 37°C and then stirred with 0.15ml of 0.15M-NaCI, 50,uM-adrenaline or 25.6,uM-ADP in the EEL titrator. At noted times three 100-,lI samples were transferred into lOO,Al of EDTA-ethanol. After 6min ofstirring (which gave maximal secondary aggregation in samples without aspirin) 0.1 ml of 77mM-EDTA (pH 7.4) was added and cells and plasma were separated. The average total radioactivity was 92000c.p.m./ml and the platelets contained 3.27 and 2.24,umol/1011 platelets of ATP and ADP respectively. (Table 7) .
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Time-course of ATP-hypoxanthine conversion during optimum biphasic aggregation after all the adenine had been metabolized On addition of ADP to labelled, stirred plasma, the ATP+ADP radioactivity always decreased immediately and hypoxanthine formation was evident after 20s (Fig. 4d) . A transient, small accumulation of radioactive IMP sometimes occurred before the rise in hypoxanthine radioactivity, but no changes in the ADP radioactivity were observed. Time (min) Fig. 6 . Variation in the radioactivity of ATP (o), ADP (El), hypoxanthine (A) and adenine (v) during stirring of 1 .8 ml oflabelledplatelet-rich plasma with 0.2 ml ofaggregating agent or its solvent in the EEL titrator at 37°C Samples (200,u1) were transferred at noted times into 200,u1 of EDTA-ethanol for determination of metabolite radioactivity. For (a) and (b) platelet-rich plasma (lOml; 2.94 x 108 platelets/ml) was incubated with 0.75 ml of 16.7buM-[3H]adenine at 37°C. After 19min of incubation one sample was stirred with 5,M-adrenaline (a), and after 28.5 min of incubation another sample was stirred with 0.15 M-NaCl (b). The zero-time in the above Figures refers to addition of adrenaline or saline. Metabolite radioactivity is expressed in % of the sum of all metabolite radioactivities (average: 380000c.p.m./ml of reaction mixture). For (c) platelet-rich plasma (lOml; 5.7 x 108 platelets/ml) was incubated with 0.25 ml of 16.7 /tM-[3H]adenine at 37°C. After 2.25 min one sample was stirred with 5,uM-adrenaline. Zero-time refers to addition of adrenaline and the average sum of all metabolite radioactivities was 102000c.p.m./ml of reaction mixture. For (d) the experiment was the same as in (c) except that the plateletrich plasma contained 1.5 x 108 platelets/ml and was stirred with 1.1 uM-ADP. The average sum of all metabolite radioactivities was 108000c.p.m./ml of reaction mixture. version during the first, but only during the second phase of aggregation (Fig. 5) . This difference from ADP-induced aggregation was evident when ADP and adrenaline were used with the same radioactive platelet-rich plasma, and was not dependent on the adrenaline concentration. In some plasma preparations adrenaline did cause a continuous conversion during the first phase of aggregation, as in all experiments with ADP. Although the rate of primary aggregation was the same whether or not the platelets responded mono-or bi-phasically to an aggregating stimulus, the ATP-hypoxanthine conversion only occurred if a second phase were to follow. This is clearly shown in Fig. 4 . (Fig. 6) . Aggregation in the presence of [3H]adenine caused a burst in the incorporation of radioactivity into ATP. This usually started during the second phase of aggregation, continued after the light-transmission changes were terminated (Fig. 6) and was preceded by a 'halt' in adenine-ATP conversion. Less radioactive hypoxanthine was formed when biphasic aggregation took place early during adenine uptake, as compared with the hypoxanthine formed after all adenine had been taken up by the platelets (Table 8) .
The 3H-labelled metabolite behaviour during aggregation was most outstanding when the adenine uptake rate was greater than 1 % of the added radioactivity per min. At lower uptake rates, less impressive changes occurred, as seen from Fig. 7(a) . When the values were expressed in % of adenine radioactivity taken up by the platelets at any time (i.e. the sum of aggregated cells (Fig. 8) The accumulation of radioactivity in ATP and disappearance of adenine in platelet-rich plasma treated with ADP or adrenaline was increased (by 80-110% compared with non-aggregated cells) almost independently of the stage of biphasic aggregation (Table 9 ).
Discussion
The specific radioactivity of ATP and ADP released from labelled platelets by external ADP and adrenaline was negligible compared with that of the ATP and ADP remaining in the cells. The amounts released and the specific radioactivity of released and remaining adenine nucleotides were similar to those released and retained by collagen and thrombin. Thus ADP and adrenaline induce release of the 'storage pool' of adenine nucleotides.
Study of the effects of temperature, the ADP and adrenaline concentrations, 'second phase fatigue' and acetylsalicylic acid shows that the intracellular Vol. 129 ATP-hypoxanthine conversion is intimately connected with the release induced by ADP and adrenaline, and not with aggregation. The degree of this conversion was the same as that induced by collagen or thrombin. The ATP consumed has been termed 'release energy ATP' and is thought to energize the release reaction (Holmsen et al., 1969a) . ATPhypoxanthine conversion also occurs without release, by simultaneous inhibition of glycolysis and respiration, and is markedly increased when release is conducted in the presence of metabolic inhibitors (Ball et al., 1969) . The ATP-hypoxanthine conversion occurring during release could thus represent the ATP that had been utilized, but not immediately compensated for by ATP resynthesis . Other factors must also be considered such as the increased formation of hypoxanthine during adenine uptake by aggregated platelets after actual release and the increased synthesis of ATP from adenine. The burst in adenine uptake has been shown to be connected with the disc-sphere transformation (Sixma et al., 1972) , which takes place during aggregation, and is probably not caused by lowering of the concentration of metabolic ATP. The somewhat catabolic metabolism of adenine during this increased uptake by aggregated platelets might be due to the small fraction of platelets undergoing lysis. Our results indicate that less than one-third of the ATPhypoxanthine conversion measured during release was due to catabolism in aggregated platelets.
The ATP-hypoxanthine conversion might be used as a marker for intracellular reactions connected with platelet secretion. With ADP it starts immediately, suggesting that some intracellular reactions underlying secretion take place before actual release can be Treatment NaCl ADP ADP ADP ADP ADP seen during the first aggregation phase when a second phase is to follow. The conversion was absent during the first phase when the second phase did not follow, further indicating that the ATP-hypoxanthine conversion is not connected with aggregation per se. Its presence during the first phase when release was to follow irnplies that aggregation by ADP is not a prerequisite for release, in contrast with the view (O'Brien, 1968b , Massini & LUischer, 1971 ) that close cell-contact is the release inducer during biphasic aggregation.
With adrenaline the ATP-hypoxanthine conversion often started after the second aggregation phase became apparent, indicating that the stimulus for release was not received by the platelets until the second phase of aggregation started. Since ADPinduced release always caused immediate ATPhypoxanthine conversion, it is possible that most of release during the adrenaline-platelet interaction was induced by the ADP appearing extracellularly. It might even be caused by a combination of adrenaline and ADP liberated by lysis of some few platelets, since adrenaline is a powerful potentiator of ADPinduced platelet aggregation (Mills & Roberts, 1967) . This also is in agreement with the distinctly smaller degree of first-phase aggregation seen with adrenaline than ADP.
Release reaction was always accompanied by ATPhypoxanthine conversion, whereas a small conversion without release took place with ADP at 290C and when release was inhibited by aspirin. This does not necessarily obviate the connexion between release and ATP-hypoxanthine conversion. On releasestimulus the cell answers with a diminished ATPhypoxanthine conversion, whereas one of the later steps in the secretion process, membrane fusion, might be more severely inhibited, so that emptying of the granule contents does not occur in spite of the intracellular processes.
Less formation of radioactive hypoxanthine took place when aggregation was conducted at an early stage of adenine uptake than at later stages. Thus the ATP just formed from adenine does not equilibrate immediately with the bulk of the metabolically active nucleotide pool, or with that special pool ofATP converted into hypoxanthine, the 'release energy pool'. This was substantiated by the difference in the kinetics of adenine and ATP metabolism at different rates of isotope uptake.
